{"entity":{"id":"cancer-drivers-vs-actionable","kind":"term","name":"Actionable genomic biomarkers","aka":["actionable genomic biomarkers","actionable alteration","actionable alterations","actionable mutation","actionable mutations","actionable biomarker","clinically actionable"],"tldr":"An actionable alteration is a change in a tumour's DNA that maps directly to an approved or investigational drug, so finding it changes what the patient is offered.","summary":"Precision or personalised medicine tailors decisions to the patient's predicted response based on molecular features (Wikipedia). In oncology a genomic alteration is called actionable when an approved drug, a guideline recommendation or an open trial is tied to it; OncoKB and CIViC grade the evidence in tiers. Actionability is narrower than being a driver: many drivers have no drug, and some drug targets (HER2 amplification) are actionable regardless of driver status.","asOf":"2026-09-24","wikipedia":"https://en.wikipedia.org/wiki/Personalized_medicine","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Personalized_medicine"}],"tags":["cansim-terms"],"related":["oncokb","civic","cancer-ai-vocabulary"],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["driver-mutation","biomarker"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Listed in the CanSim terms map 1.0.0 (docs/onco/terms.json, generated 2026-09-24), CC BY 4.0, attribution: CanSim project, an open, public-data-first cancer foundation-model programme; CanSim page path /terms/actionable-genomic-biomarkers."],"provenance":{"editedBy":"OnCo CanSim terms wave (Wikipedia summaries, standards and project pages, GDC and FDA pages, Europe PMC)","editedOn":"2026-09-24","note":"CanSim terms map 1.0.0 (docs/onco/terms.json, generated 2026-09-24), CC BY 4.0, attribution: CanSim project, an open, public-data-first cancer foundation-model programme"},"category":"Biomarkers"},"route":"/terms/cancer-drivers-vs-actionable/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"oncokb","kind":"collection","name":"OncoKB","route":"/collections/oncokb/"}],"term":[{"id":"biomarker","kind":"term","name":"Biomarker","route":"/terms/biomarker/"},{"id":"cancer-ai-vocabulary","kind":"term","name":"Cancer AI vocabulary (CanSim terms map)","route":"/terms/cancer-ai-vocabulary/"},{"id":"driver-mutation","kind":"term","name":"Driver mutation","route":"/terms/driver-mutation/"},{"id":"pharmacogenomics-term","kind":"term","name":"Pharmacogenomics","route":"/terms/pharmacogenomics-term/"},{"id":"targeted-panel-sequencing","kind":"term","name":"Targeted panel sequencing","route":"/terms/targeted-panel-sequencing/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"}]}}